AI firms run virtual drug trials to raise the odds of success in human studies
AI Market Summary
The report highlights growing use of AI-driven virtual clinical trial simulations to screen drug candidates and reduce late-stage failure risk. While broad adoption could lower R&D costs and improve pipeline efficiency across biotech and pharma, the evidence remains mixed, with notable misses on high-profile trials. Near-term market impact is likely incremental, influencing investor focus on R&D productivity, trial-risk assessment, and M&A diligence.
Impact level
● Low
Affected assets
NCSKMRNA2USD/USDT+3.90%
AI Insight · NCSKMRNA2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
AI companies are running virtual drug trials in an effort to improve the success rate of human clinical studies. Novartis’ once‑touted del-desiran missed its target in a late-stage trial, sending the stock down 11% in a single session and wiping out $30 billion in market value. Takeda’s head of research said the TYK2 target was identified through human genetics analysis, and machine learning was used to refine the structure of a once-daily oral pill.
